Navigation Links
Anpath Group, Inc. Distributor Introduces Products at the Japanese Society of Intensive Care Medicine Annual Meeting
Date:5/14/2009

MOORESVILLE, N.C., May 14 /PRNewswire-FirstCall/ -- Anpath Group, Inc. (OTC Bulleting Board: ANPG), announced today that its wholly-owned subsidiary, EnviroSystems, Inc. (ESI) and its distributor partner, Minntech Japan Corporation, launched the ESI product line at the recent 36th annual meeting of the Japanese Society of Intensive Care Medicine held in Osaka, Japan.

The annual meeting was attended by over 4,000 medical professionals. The Company reported that Minntech Japan received positive feedback regarding ESI's disinfectant cleaner, EnviroTru(R), and the distributor is currently contacting interested parties as part of the overall launch plan. According to Mr. Mike Kitamura, Managing Director, Minntech Japan Corporation, nurses and medical technicians demonstrated a high level of interest in EnviroTru(R) because of its safety and material compatibility profile. Mr. Kitamura also stated that Minntech Japan plans to display EnviroTru(R) at the Japanese Society for Dialysis Therapy next month. Approximately 15,000 attendees are expected at that meeting.

EnviroTru(R) is a multi-purpose disinfectant and deodorizing cleaner effective against numerous organisms, and also meets EPA requirements for Toxicity Category IV (no harmful dermal, ocular, inhalation or ingestion effects). EnviroTru(R) does not require protective clothing, gloves or special ventilation and has passed the AMS 1452A, AMS 1453 and Boeing D6-7127 specifications for non-corrosion and materials compatibility.

About Anpath Group, Incorporated:

Anpath Group, Inc. (Anpath), through its wholly-owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment. Visit www.anpathgroup.com for more information.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks -- both natural and man-made. Visit www.envirosi.com for more information.

Forward Looking Statements:

This release contains forward-looking statements, which reflect expectation or belief by Anpath Group, Inc. concerning future events that involve risks and uncertainties. Anpath Group can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Anpath Group expectations, including, but not limited to EPA and state registration of the Company's products, the Company's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of its technology, the risk that products may not result from development activities, protection of its intellectual property, need for regulatory approvals, and other factors discussed in periodic Anpath Group, Inc. filings with the Securities and Exchange Commission. Forward-looking statements are qualified in their entirety by the above cautionary statement. Anpath Group assumes no duty to update its outlook or other forward-looking statements as of any future date.


'/>"/>
SOURCE Anpath Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anpath Group, Inc. Increases Market Share in Korea
2. Anpath Group, Inc. Announces Intent To Seek Shareholder Approval for a Reverse Split of Its Common Stock
3. Anpath Group, Inc. Expands International Distribution With Minntech Corporation
4. Anpath Group, Inc. Announces Appointments of David V. Gilroy and Paul A. Boyer to Board of Directors
5. Anpath Group, Inc. Announces Advancements with Animal Care Line
6. Emdeon Announces Agreement to Acquire The Sentinel Group, a Leader in Healthcare Fraud and Abuse Management Services
7. Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009
8. SOKO Fitness & Spa Group, Inc. to hold 2009 Q3 Earnings Call on Apr. 16
9. Clarity Group, Inc. Announces Launch of New Website
10. SOKO Fitness & Spa Group, Inc. Opens Xinyang Spa in Harbin
11. Hanger Orthopedic Group, Inc. Announces First Quarter 2009 Earnings Release Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, comedic content, ... series that uses humor to highlight ways to improve heart health and overall well-being. ... movement, which is designed to inspire all Americans to make small changes that add ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at the ... internship in internal medicine at the Emory University and dermatology training at the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for patients with sleep apnea and TMJ disorders. These conditions are quite common ... Dr. Rassouli provides personalized care to reduce the risk of these consequences and ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative ... Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries from ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor ... global anti-obesity drugs market is expected to grow at a ... and CAGR of 38.7% in the second half of the forecast ... 32.8% from 2016 to 2027. The market is estimated at $1,058 ... 2027. ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
(Date:1/19/2017)... New Review of Safinamide ... Symptoms and Motor Complications in Mid- to Late-stage ... ... C Warren Olanow ... 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published ...
Breaking Medicine Technology: